Disease factsheet about rotavirus
Rotaviruses are the single most important cause of severe diarrhoeal illness in infants and young children worldwide. By the age of five years most children irrespective of socioeconomic setting will have been infected at least once. While infected, many children will be in need of medical attention due to extensive fluid loss.
Prevention and control measures for rotavirus
Two rotavirus vaccines were authorised for prevention of rotavirus gastroenteritis in 2006. Authorised vaccines provide a high level of protection against severe disease in need of medical attention. Evidence suggests that rotavirus vaccination should be initiated before 12 weeks of age and can be administered together with other infant vaccines.
Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in AustriaArchived
This paper describes the epidemiology of rotavirus (RV) in Austrian children before and during universal mass campaign.
Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trialArchived
These article published in The Lancet provide new data for the efficacy of oral pentavalent rotavirus vaccine for prevention of severe rotavirus – related gastroenteritis in infant in developing countries
Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in IrelandArchived
Rotavirus gastroenteritis in Ireland is a quite common and unpleasant illness, but severe disease is unusual and death extremely rare. Nonetheless, rotavirus generates considerable direct and indirect costs.
Safety, Reactogenicity and Immunogenicity of the Human Rotavirus Vaccine in Pre-Term European Infants: A Randomized Phase IIIb StudyArchived
Results of this study demonstrated that the RIX4414 vaccine was well tolerated and immunogenic in pre-term European infants: more than 75% of infants had seroconverted 30-83 days after dose 2.
Effectiveness of rotavirus vaccination: Generic study protocols for retrospective case control and cohort studies based on computerised databases
In Europe, routine rotavirus vaccination of infants at the national level has been introduced with one or two vaccine brands in Finland, Austria, Luxembourg and Belgium within well-baby clinics or administered by general practitioners and paediatricians. When introducing a new vaccine, it is crucial to conduct studies evaluating the vaccination’s impact and effectiveness in order to decide on recommendations for its future use.